[How to use PDE III inhibitors].
Goto
Yoichi
Y
Division of Cardiology, Department of Medicine, National Cardiovascular Center.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000208:Acute Disease; D001794:Blood Pressure; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007093:Imidazoles; D020105:Milrinone; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D017410:Practice Guidelines as Topic; D011728:Pyridones; D016032:Randomized Controlled Trials as Topic
D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; C059498:olprinone; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D020105:Milrinone